The peptide restored glucose metabolism markers including improved glucose disappearance rates and normalized insulin response peaks, suggesting restoration of pancreatic and metabolic function to more youthful states
Pharmacokinetic studies have characterized IGF1 LR3s absorption, distribution, body function, and excretion
References Product warnings updated for GLP-1 RA class, 01 December 2025, Therapeutic Good Administrations, GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours, 01 December 2025, Therapeutic Good Administration, Updated contraception advice for Mounjaro (tirzepatide), 01 December 2025, Therapeutic Good Administrations, GLP-1 medicines for weight loss and diabetes: what you need to know, 20 August 2025, Medicine and Healthcare Product Regulatory Agency, Australias drug regulator issues mental health warning for weight-loss drugs including Ozempic, 01 December 2025,
10.1016/j.jsbmb.2004.10.019 119 RobertsM
